Description of the upcoming change in data analysis for USP dissolution performance verification tests

Walter W. Hauck, Anthony J. DeStefano, William E. Brown, Erika S. Stippler, Darrell R. Abernethy, Roger L. Williams, Thomas S. Foster, James E. Polli, Diane J. Burgess, G. Bryan Crist, Mario A. Gonzalez, Vivian A. Gray, Johannes Kraemer, Lewis J. Leeson, Alan F. Parr, Leon Shargel, Eli Shefter, W. Craig Simon, Nhan L. Tran, Clarence T. Ueda

Research output: Contribution to journalArticle

Abstract

As part of its evaluation of the performance verification tests used periodically to affirm the integrity of the USP Performance test when General Chapter Dissolution (711) is relied upon, the Biopharmaceutics Expert Committee of the Council of Experts, working with staff, decided to change the form of the accept/reject decision from one based on the result for each tablet to one based on the mean and coefficient of variation of results from a set of tablets. This paper describes the new approach. The paper also describes an implementation period for the approach, coupled with a period during which USP will discontinue use of the Salicylic Acid tablet in a performance verification test.

Original languageEnglish (US)
Pages (from-to)1630-1634
Number of pages5
JournalPharmacopeial Forum
Volume34
Issue number6
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Tablets
Dissolution
Biopharmaceutics
Salicylic Acid

ASJC Scopus subject areas

  • Drug guides
  • Pharmacy
  • Pharmacology

Cite this

Hauck, W. W., DeStefano, A. J., Brown, W. E., Stippler, E. S., Abernethy, D. R., Williams, R. L., ... Ueda, C. T. (2008). Description of the upcoming change in data analysis for USP dissolution performance verification tests. Pharmacopeial Forum, 34(6), 1630-1634.

Description of the upcoming change in data analysis for USP dissolution performance verification tests. / Hauck, Walter W.; DeStefano, Anthony J.; Brown, William E.; Stippler, Erika S.; Abernethy, Darrell R.; Williams, Roger L.; Foster, Thomas S.; Polli, James E.; Burgess, Diane J.; Crist, G. Bryan; Gonzalez, Mario A.; Gray, Vivian A.; Kraemer, Johannes; Leeson, Lewis J.; Parr, Alan F.; Shargel, Leon; Shefter, Eli; Simon, W. Craig; Tran, Nhan L.; Ueda, Clarence T.

In: Pharmacopeial Forum, Vol. 34, No. 6, 11.2008, p. 1630-1634.

Research output: Contribution to journalArticle

Hauck, WW, DeStefano, AJ, Brown, WE, Stippler, ES, Abernethy, DR, Williams, RL, Foster, TS, Polli, JE, Burgess, DJ, Crist, GB, Gonzalez, MA, Gray, VA, Kraemer, J, Leeson, LJ, Parr, AF, Shargel, L, Shefter, E, Simon, WC, Tran, NL & Ueda, CT 2008, 'Description of the upcoming change in data analysis for USP dissolution performance verification tests', Pharmacopeial Forum, vol. 34, no. 6, pp. 1630-1634.
Hauck WW, DeStefano AJ, Brown WE, Stippler ES, Abernethy DR, Williams RL et al. Description of the upcoming change in data analysis for USP dissolution performance verification tests. Pharmacopeial Forum. 2008 Nov;34(6):1630-1634.
Hauck, Walter W. ; DeStefano, Anthony J. ; Brown, William E. ; Stippler, Erika S. ; Abernethy, Darrell R. ; Williams, Roger L. ; Foster, Thomas S. ; Polli, James E. ; Burgess, Diane J. ; Crist, G. Bryan ; Gonzalez, Mario A. ; Gray, Vivian A. ; Kraemer, Johannes ; Leeson, Lewis J. ; Parr, Alan F. ; Shargel, Leon ; Shefter, Eli ; Simon, W. Craig ; Tran, Nhan L. ; Ueda, Clarence T. / Description of the upcoming change in data analysis for USP dissolution performance verification tests. In: Pharmacopeial Forum. 2008 ; Vol. 34, No. 6. pp. 1630-1634.
@article{bef0a0e9635044adafdafe9ba5f40820,
title = "Description of the upcoming change in data analysis for USP dissolution performance verification tests",
abstract = "As part of its evaluation of the performance verification tests used periodically to affirm the integrity of the USP Performance test when General Chapter Dissolution (711) is relied upon, the Biopharmaceutics Expert Committee of the Council of Experts, working with staff, decided to change the form of the accept/reject decision from one based on the result for each tablet to one based on the mean and coefficient of variation of results from a set of tablets. This paper describes the new approach. The paper also describes an implementation period for the approach, coupled with a period during which USP will discontinue use of the Salicylic Acid tablet in a performance verification test.",
author = "Hauck, {Walter W.} and DeStefano, {Anthony J.} and Brown, {William E.} and Stippler, {Erika S.} and Abernethy, {Darrell R.} and Williams, {Roger L.} and Foster, {Thomas S.} and Polli, {James E.} and Burgess, {Diane J.} and Crist, {G. Bryan} and Gonzalez, {Mario A.} and Gray, {Vivian A.} and Johannes Kraemer and Leeson, {Lewis J.} and Parr, {Alan F.} and Leon Shargel and Eli Shefter and Simon, {W. Craig} and Tran, {Nhan L.} and Ueda, {Clarence T.}",
year = "2008",
month = "11",
language = "English (US)",
volume = "34",
pages = "1630--1634",
journal = "Pharmacopeial Forum",
issn = "0363-4655",
publisher = "United States Pharmacopeial Convention Inc.",
number = "6",

}

TY - JOUR

T1 - Description of the upcoming change in data analysis for USP dissolution performance verification tests

AU - Hauck, Walter W.

AU - DeStefano, Anthony J.

AU - Brown, William E.

AU - Stippler, Erika S.

AU - Abernethy, Darrell R.

AU - Williams, Roger L.

AU - Foster, Thomas S.

AU - Polli, James E.

AU - Burgess, Diane J.

AU - Crist, G. Bryan

AU - Gonzalez, Mario A.

AU - Gray, Vivian A.

AU - Kraemer, Johannes

AU - Leeson, Lewis J.

AU - Parr, Alan F.

AU - Shargel, Leon

AU - Shefter, Eli

AU - Simon, W. Craig

AU - Tran, Nhan L.

AU - Ueda, Clarence T.

PY - 2008/11

Y1 - 2008/11

N2 - As part of its evaluation of the performance verification tests used periodically to affirm the integrity of the USP Performance test when General Chapter Dissolution (711) is relied upon, the Biopharmaceutics Expert Committee of the Council of Experts, working with staff, decided to change the form of the accept/reject decision from one based on the result for each tablet to one based on the mean and coefficient of variation of results from a set of tablets. This paper describes the new approach. The paper also describes an implementation period for the approach, coupled with a period during which USP will discontinue use of the Salicylic Acid tablet in a performance verification test.

AB - As part of its evaluation of the performance verification tests used periodically to affirm the integrity of the USP Performance test when General Chapter Dissolution (711) is relied upon, the Biopharmaceutics Expert Committee of the Council of Experts, working with staff, decided to change the form of the accept/reject decision from one based on the result for each tablet to one based on the mean and coefficient of variation of results from a set of tablets. This paper describes the new approach. The paper also describes an implementation period for the approach, coupled with a period during which USP will discontinue use of the Salicylic Acid tablet in a performance verification test.

UR - http://www.scopus.com/inward/record.url?scp=57149143074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149143074&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:57149143074

VL - 34

SP - 1630

EP - 1634

JO - Pharmacopeial Forum

JF - Pharmacopeial Forum

SN - 0363-4655

IS - 6

ER -